JAN 14, 2020 12:27 PM PST

Promising Treatment for Dementia: Antibiotics

WRITTEN BY: Nouran Amin

A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to researchers at the University of Kentucky's College of Medicine. The findings were a result of a proof-of-concept study published in the journal, Human Molecular Genetics.

Frontotemporal dementia affects the frontal and temporal lobes of the brain leading to behavioral changes, and challenges in speaking, writing, and retaining memory. It is one of the most common types of dementia second to Alzheimer's disease and typically begins between the ages 40 and 65. A certain group of individuals affected by this dementia have a mutation in their genome that prevents brain cells from manufacturing a protein called ‘progranulin’. Even though progranulin is not really widely understood its absence is believed to be linked to dementia.

Learn more about frontotemporal dementia:

"These patients' brain cells have a mutation that prevents progranulin from being made. The team found that by adding a small antibiotic molecule to the cells, they could 'trick' the cellular machinery into making it," said Matthew Gentry, a co-author of the study and the Antonio S. Turco Endowed Professor in the Department of Molecular and Cellular Biochemistry.

The antibiotic, aminoglycoside, when added to neuronal cells it starts producing the progranulin protein by completely skipping the mutation. The specific aminoglycoside antibiotics used in the study were Gentamicin and G418.

"If we can get the right resources and physician to work with, we could potentially repurpose this drug. This is an early stage of the study, but it provides an important proof of concept that these aminoglycoside antibiotics or their derivatives can be a therapeutic avenue for frontotemporal dementia," said Haining Zhu, a professor in UK's Department of Molecular and Cellular Biochemistry.

These findings could provide the basis of future drug development since there are currently no effective therapies for any type of dementia.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 16, 2020
Neuroscience
MAY 16, 2020
Stem Cell Method (Parkinson's) Could Avoid Transplant Rejection
Researchers at McLean Hospital and Massachusetts General Hospital (MGH) have tested a stem cell treatment method that av ...
MAY 14, 2020
Drug Discovery & Development
MAY 14, 2020
Therapeutic for Gastrointestinal Tumors
The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal ...
JUN 03, 2020
Cell & Molecular Biology
JUN 03, 2020
A New Insulin That's Based on Cone Snail Venom
Insulin is a hormone that's produced by a specific set of cells in the pancreas, and it functions to regulate blood ...
JUN 10, 2020
Cannabis Sciences
JUN 10, 2020
Cannabis Temporarily Relieves PTSD Symptoms
PTSD (Post Traumatic Stress Disorder) is a mental disorder characterized by flashbacks, nightmares, and severe anxiety f ...
JUL 02, 2020
Drug Discovery & Development
JUL 02, 2020
Common Asthma Drug Could Treat Alzheimer's
Researchers from Lancaster University, England, have found that Salbutamol, a medication commonly used to treat asthma, ...
JUL 08, 2020
Drug Discovery & Development
JUL 08, 2020
Common Blood Pressure Drugs May Prevent Colon Cancer
Colon cancer is the third most common cancer and the second leading cause of death by cancer around the world. Now, rese ...
Loading Comments...